Carvedilol versus Metoprolol for the Prevention of Atrial Fibrillation After Off-Pump Coronary Bypass Surgery: Rationale and Design of the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial (COMPACT)
- 218 Downloads
Postoperative new-onset atrial fibrillation (AF) remains the most common complication of coronary artery bypass graft surgery. Postoperative AF carries the risk of hemodynamic instability, increases the risk of thromboembolic events, and has a significant economic impact. Current guidelines recommend treatment with β-blockers to prevent AF; information, however, is limited regarding the relative efficacy of β-blocking agents. Carvedilol is a non-selective adrenergic blocker with anti-inflammatory, antioxidant, and multiple cationic channel blocking properties. These unique properties of carvedilol have generated interest in its use as a prophylaxis for postoperative AF.
Materials and methods
We hypothesize that carvedilol will be more effective than metoprolol, a conventional β1-selective antagonist, in suppressing newly developed AF following off-pump coronary artery bypass (OPCAB) surgery. We have designed the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial (COMPACT) to test our hypothesis in a multi-center, open-label, randomized, and controlled trial. A total of at least 650 patients will be randomized to receive an initial oral dose of either 5 mg of carvedilol twice per day or 20 mg of metoprolol tartrate three times per day following surgery. The dose of each β-blocker will be increased to the maximum tolerated dose. The primary endpoint is the incidence of new-onset AF during the first 7 days after surgery.
The COMPACT is the first multi-center, randomized, controlled trial to directly compare two different β-blockers in patients following surgical coronary revascularization. Results of this trial will help to guide physicians in choosing appropriate medications following OPCAB surgery.
Key wordsadrenergic beta-antagonists carvedilol coronary artery bypass atrial fibrillation
Unable to display preview. Download preview PDF.
- 1.Ommen SR, Odell JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. [published erratum appears in N Engl J Med 1997 Jul 17;337(3):209]. N Engl J Med 1997;336:1429–34.Google Scholar
- 3.Mathew JP, Fontes ML, Tudor IC, et al. Investigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004;291:1720–9.Google Scholar
- 10.Eagle KA, Guyton RA, Davidoff R, et al. American Heart Association. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004;110:e340–437.Google Scholar
- 24.Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118–50.PubMedGoogle Scholar
- 25.Hosmer DW, Lemeshow S. Applied logistic regression, 2nd ed. London: Wiley; 2000.Google Scholar